Bicara Therapeutics (NASDAQ:BCAX) Upgraded by BMO Capital Markets to Strong-Buy Rating

BMO Capital Markets upgraded shares of Bicara Therapeutics (NASDAQ:BCAX) to a strong-buy rating in a research note released on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th. Mizuho boosted their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. The Goldman Sachs Group raised their price objective on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.64.

Bicara Therapeutics Stock Up 3.8%

Shares of Bicara Therapeutics stock opened at $25.86 on Tuesday. Bicara Therapeutics has a 12 month low of $10.30 and a 12 month high of $30.99. The stock has a market cap of $1.71 billion, a PE ratio of -8.34 and a beta of -0.75. The business has a fifty day simple moving average of $26.44 and a 200 day simple moving average of $22.02.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts’ consensus estimates of ($0.82). Analysts expect that Bicara Therapeutics will post -3.45 EPS for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In related news, CEO Claire Mazumdar sold 10,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $279,800.00. Following the transaction, the chief executive officer owned 362,152 shares in the company, valued at $10,133,012.96. The trade was a 2.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,632,044.35. This trade represents a 8.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 108,000 shares of company stock worth $3,079,236. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BCAX. Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics in the 4th quarter valued at approximately $45,000. Larson Financial Group LLC grew its position in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.